This content is machine translated Precision therapy Targeted MET inhibition after progression with osimertinib Despite the success of osimertinib, a third-generation EGFR-TKI, in first-line therapy, the treatment of NSCLC after progression remains a challenge. SAVANNAH and ORCHARD have investigated the targeted addition of additional...…
View Post 3 min This content is machine translated Immunotherapy Subcutaneously or intravenously? New data on the efficacy of subcutaneous immunotherapies versus intravenous therapies in NSCLC underline not only the benefits for patients but also for healthcare professionals. This is shown by analyses...…
View Post 0 min This content is machine translated Inoperable NSCLC Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy ... Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich Jetzt beitretenAlready a member? Log in here
